Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 701-710 of 982 for hematology

Edit search filters
  1. A Study of LY2784544 for Patients with Myeloproliferative Disorders

    Scottsdale/Phoenix, AZ

  2. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  3. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

    Rochester, MN

  4. Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

    Rochester, MN

  5. PAC203: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000 _l29_="" />

    Scottsdale/Phoenix, AZ

  6. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML

    Jacksonville, FL, Rochester, MN

  8. Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer